Chromadex Corp
NASDAQ:CDXC

  • LAST PRICE
    3.8000
  • TODAY'S CHANGE (%)
    0.0200 (0.5291%)
  • Bid / Lots
    3.7200/ 3
  • Ask / Lots
    3.8200/ 1
  • Open / Previous Close
    3.8500 / 3.7800
  • Day Range
    3.7300
    3.8900
  • 52 Week Range
    1.2500
    4.6500
  • Volume
    174,193

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • Sep 20, 2024

      Show headlines and story abstract

    • 10:00AM ET on Friday Sep 20, 2024 by MT Newswires
      Companies Mentioned: ATNF, CDXC
      10:00 AM EDT, 09/20/2024 (MT Newswires) -- ChromaDex (CDXC) said Friday it has appointed Ozan Pamir as chief financial officer, starting Oct. 21. Pamir is joining the company from 180 Life Sciences (ATNF), where he most recently served as the CFO, C...

    • 8:51AM ET on Friday Sep 20, 2024 by Dow Jones
      Companies Mentioned: ATNF, CDXC

      By Dean Seal

      ChromaDex has hired the outgoing chief financial officer of 180 Life Sciences.

      The dietary supplement and food ingredient company said Friday that Ozan Pamir will take over as financial chief on Oct. 21. He succeeds Comptroller James Lee, who was serving in the role on an interim basis following the departure of Brianna Gerber in July.

    • 8:32AM ET on Friday Sep 20, 2024 by Dow Jones
      Companies Mentioned: CDXC

    • 8:32AM ET on Friday Sep 20, 2024 by Dow Jones
      Companies Mentioned: CDXC

      Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents related to Niagen IV; the Company's ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of the Company's products; the Company's reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with the Company's business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Peers Headlines